drugset
drugset / Trial / NCT04033341

A Study of LY3214996 in Healthy Participants

NCT04033341 ↗

Phase 1 Completed 6 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelBasic science

Summary

The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to get rid of it. This study will involve a single dose of 14C radiolabelled LY3214996. This means that a radioactive substance, C14, will be incorporated into the study drug. The purposes are to investigate the study drug and its breakdown products and to find out how much of these pass from blood into urine and feces. The study will last up to six weeks.

Timeline

Start
2019-08-01
Primary completion
2019-09-09
Completion
2019-09-09

Drugs

EvaluationDrugModalityDoseRoute
Subject TEMUTERKIB Small molecule — Oral

Indications

No indication recorded.